Steering anti-cancer drugs away from the TRAIL

被引：0
|
作者：
Shigekazu Nagata
机构：
[1] Osaka University Medical School and Core Research for Evolutional Science and Technology,Department of Genetics
[2] Japan Science and Technology Corporation,undefined
来源：
Nature Medicine | 2000年 / 6卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
TRAIL, a cytokine of the TNF family, has been hyped as an almost ‘magical’ drug for cancer treatment. However, its possible side effects in the liver raise serious concerns about its likelihood for development into a safe therapeutic product (pages 564–567 ).
引用
收藏
页码：502 / 503
页数：1
相关论文
共 50 条
  • [1] Steering anti-cancer drugs away from the TRAIL
    Nagata, S
    NATURE MEDICINE, 2000, 6 (05) : 502 - 503
  • [2] Anti-cancer drugs
    Bergmann-Leitner, ES
    CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (09) : 1077 - 1078
  • [3] Anti-cancer drugs
    Bergmann-Leitner, Elke
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (11) : 1048 - 1048
  • [4] Anti-Cancer Drugs
    Bergmann-Leitner, Elke
    CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (07) : 730 - 731
  • [5] TRAIL as a target in anti-cancer therapy
    Wu, Gen Sheng
    CANCER LETTERS, 2009, 285 (01) : 1 - 5
  • [6] From microtubule dynamics to anti-cancer drugs
    Mitchison, T. J.
    MOLECULAR BIOLOGY OF THE CELL, 2013, 24
  • [7] BETTER PROTECTION FROM ANTI-CANCER DRUGS
    GANNON, E
    RN MAGAZINE, 1985, 48 (05): : 9 - 9
  • [8] Teratogens as anti-cancer drugs
    Blagosklonny, MV
    CELL CYCLE, 2005, 4 (11) : 1518 - 1521
  • [9] Development of Anti-cancer Drugs
    Arrondeau, Jennifer
    Gan, Hui K.
    Razak, Albiruni R. A.
    Paoletti, Xavier
    Le Tourneau, Christophe
    DISCOVERY MEDICINE, 2010, 10 (53) : 355 - 362
  • [10] HANDLING ANTI-CANCER DRUGS
    不详
    LANCET, 1983, 1 (8323): : 543 - 543
12345